Companies › Alpha-9 Oncology USA
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [177Lu]Lu-A9-0631 Lutetium-177 labeled GRPR-targeting peptide | GRPR | Phase 1 | Breast Cancer | Dec 2028 |
| [225Ac]Ac-A9-0642 Actinium-225 labeled GRPR-targeting peptide | GRPR | Phase 1 | Breast Cancer | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07661641 | [177Lu]Lu-A9-0631 | Phase 1 | Breast Cancer | Oncology | Dec 2028 |
| NCT07661641 | [225Ac]Ac-A9-0642 | Phase 1 | Breast Cancer | Oncology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.